At Linker Sciences, we are industry-focused scientists with deep expertise in mass spectrometry who recognized a critical gap in the early phases of drug discovery. We are building a platform that leverages high-resolution mass spectrometry, automated sample handling, and machine learning to accelerate the identification and validation of small-molecule therapeutics.
"Our approach addresses key inefficiencies in current drug screening methods by integrating experimental and computational tools into a unified, scalable system. We are launching Linker Sciences to translate this vision into a next-generation discovery engine tailored for pharmaceutical R&D and CRO integration."
Mass Spectrometry
Synthetic Biology
Challenging Targets
Informatics and AI